ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD Stock Report

Market Cap: US$2.8b

ACADIA Pharmaceuticals Future Growth

Future criteria checks 4/6

ACADIA Pharmaceuticals is forecast to grow earnings and revenue by 28% and 9.4% per annum respectively. EPS is expected to grow by 25.5% per annum. Return on equity is forecast to be 19.5% in 3 years.

Key information

28.0%

Earnings growth rate

25.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate9.4%
Future return on equity19.5%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 08
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 27

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 11

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 08
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 26

The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Apr 24
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue

Mar 12

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing

Feb 29

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

Jan 23

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jan 03
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Dec 04
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

May 22
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah

Oct 19

FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide

Sep 12

Acadia: Powerful Unfolding Catalysts

Aug 03

Earnings and Revenue Growth Forecasts

NasdaqGS:ACAD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,15621320326814
12/31/20251,05514016223418
12/31/202497412015725519
9/30/2024929129203203N/A
6/30/2024891318081N/A
3/31/2024814-22464N/A
12/31/2023726-61-2317N/A
9/30/2023632-149-133-93N/A
6/30/2023551-111-74-34N/A
3/31/2023520-146-56-56N/A
12/31/2022517-216-114-114N/A
9/30/2022512-217-113-113N/A
6/30/2022512-205-130-130N/A
3/31/2022493-214-142-142N/A
12/31/2021484-168-127-126N/A
9/30/2021474-192-133-130N/A
6/30/2021463-262-141-136N/A
3/31/2021458-260-155-147N/A
12/31/2020442-282-144-136N/A
9/30/2020419-268-144-138N/A
6/30/2020393-225-139-134N/A
3/31/2020366-238-137-136N/A
12/31/2019339-235-152-151N/A
9/30/2019300-248-162-161N/A
6/30/2019264-268-186-184N/A
3/31/2019238-276-189-186N/A
12/31/2018224-245-170-167N/A
9/30/2018208-249-160-158N/A
6/30/2018185-252N/A-174N/A
3/31/2018158-256N/A-192N/A
12/31/2017125-289N/A-218N/A
9/30/201793-299N/A-251N/A
6/30/201763-306N/A-242N/A
3/31/201733-309N/A-240N/A
12/31/201617-271N/A-208N/A
9/30/20165-238N/A-182N/A
6/30/20160-206N/A-165N/A
3/31/20160-174N/A-138N/A
12/31/20150-164N/A-122N/A
9/30/20150-147N/A-105N/A
6/30/20150-133N/A-91N/A
3/31/20150-115N/A-78N/A
12/31/20140-92N/A-66N/A
9/30/20140-76N/A-59N/A
6/30/20140-62N/A-51N/A
3/31/20141-50N/A-39N/A
12/31/20131-38N/A-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACAD's forecast earnings growth (28% per year) is above the savings rate (2.6%).

Earnings vs Market: ACAD's earnings (28% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: ACAD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ACAD's revenue (9.4% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ACAD's revenue (9.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACAD's Return on Equity is forecast to be low in 3 years time (19.5%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:01
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Joel BeattyBaird
Ishan MajumdarBaptista Research